We are pleased to announce that as of today the Draft Project Plan on “Transcatheter mitral valve repair in adults with chronic mitral valve regurgitation”, produced within WP5 Strand B, has entered the public consultation phase.
The open access article “European collaboration on relative effectiveness assessments: What is needed to be successful?” (Kleijnen S, et al. Health Policy (2015)), sets out to identify the possible barriers and success factors for the implementation of European collaboration on REAs of drugs.
The Joint Assessment of WP5 Strand A on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma is now available.
The joint rapid assessment of WP5 Strand A evaluates ‘sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine’ is available.
National uptake of the EUnetHTA output is one practical example illustrating the implementation of EUnetHTA’s vision and mission. This page provides insights into the process of national uptake of the joint work carried out by EUnetHTA - the technical and scientific cooperation of the HTA Network.
EUnetHTA brings added value to healthcare systems not only at the European level, but also at the national and regional healthcare systems level by promoting standardised approaches across Europe while respecting national competences in the healthcare area.
A joint assessment is structured information for rapid or full HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes*.
Methodological guidelines for rapid relative effectiveness assessment (REA) of Pharmaceuticals are guidelines on methodological challenges that are encountered by health technology assessors while performing a rapid REA of pharmaceuticals.
The primary aim of the guidelines is to help the assessors of evidence interpret and process the data that are presented to them as part of a REA.
The aim of the Glossary of HTA Adaptation Terms is to identify and highlight key words and concepts that are easily misunderstood between countries with a view to aiding the adaptation of HTA reports between settings. It provides a series of descriptions for such terms and contains examples of where the usage of these terms may differ between countries.
The EUnetHTA Stakeholder Forum is formed to ensure a transparent engagement with a broad range of stakeholders and is comprised of representatives from patient and healthcare consumer organisations, healthcare providers, payers (statutory health insurance) and the industry. The Stakeholder Forum's composition aims at ensuring broad and balanced representation of stakeholder interests.
Under "contact us", you will find a list of all Stakeholder members with an indication of which group they belong to in parenthesis.
Organisations representing interests of four stakeholder groups – patients/consumers, industry, payers (statutory health insurance) and healthcare providers can participate via the EUnetHTA Stakeholder Forum.
Public Consultations are held regularly as a form of soliciting public input on the draft documents produced by EUnetHTA within the framework of implementing the EUnetHTA Joint Action 2 grant agreement and 3-year EUnetHTA Joint Action 2 Work Plan.
Announcements of the public consultations are made in the "News" section of this website.
The full list of public consultations (ongoing or closed) is available in the "Get involved" section of this website